Lymphoproliferative disorders following allogeneic bone marrow transplantation: The Vancouver experience

Bone Marrow Transplantation

Volumn 22, Issue 10, 1998, Pages 981-987

  Micallef, I N M ^a   Chhanabhai, M ^a   Gascoyne, R D ^a   Shepherd, J D ^a   Fung, H C ^a   Nantel, S H ^a   Toze, C L ^a   Klingemann, H G ^a   Sutherland, H J ^a   Hogge, D E ^a   Nevill, T J ^a   Le, A ^a   Barnett, M J ^a,b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b VANCOUVER GENERAL HOSPITAL   (Canada)

Author keywords

Allogeneic BMT; EBV; Lymphoma; PTLD

Indexed keywords

CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; METHOTREXATE; THYMOCYTE ANTIBODY; XOMAZYME;

ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOPSY; B CELL LYMPHOMA; B LYMPHOCYTE; CANADA; CELL HYPERPLASIA; DISEASE COURSE; EPSTEIN BARR VIRUS; FEMALE; FEVER; GRAFT VERSUS HOST REACTION; HUMAN; LIVER DISEASE; LUNG DISEASE; LYMPHADENOPATHY; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MORPHOLOGY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPHYLAXIS; T LYMPHOCYTE;

EID: 0031751221     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701468     Document Type: Article

References (24)

1. Hanto DW, Frizzera G, Gajl-Peczalska KJ, Simmons RL. Epstein-Barr virus, immunodeficiency, and B cell lymphopro liferation. Transplantation 1985; 39: 461-472.
2. Shapiro RS, McClain K, Frizzera G et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood 1988; 71: 1234-1243.
3. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
4. Gerritsen EJA, Stam ED, Hermans J et al. Risk factors for developing EBV-related B cell lymphoproliferative disorders (BLPD) after non-HLA-identical BMT in children. Bone Marrow Transplant 1996; 18: 377-382.
5. Orazi A, Hromas RA, Neiman RS et al. Posttransplantation lymphoproliferative disorders in bone marrow transplant recipients are aggressive diseases with a high incidence of adverse histologic and immunobiologic features. Am J Clin Pathol 1997; 107: 419-429.
6. + cells from allogeneic bone marrow grafts using high gradient magnetic separation (HGMS). Blood 1994; 84: (Suppl. 1): 101 a (Abstr. 393).
7. Storb R, Deeg HJ, Whitehead J et al, Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. New Engl J Med 1986; 314: 729-735.
8. Glucksberg H, Storb R, Fefer A et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18: 295-304.
9. Weisdorf DJ, Snover DC, Haake R et al. Acute upper gastrointestinal graft-versus-host disease: clinical significance and response to immunosuppressive therapy. Blood 1990; 76: 624-629.
10. Chhanabhai M, Adomat SA, Gascoyne RD, Horsman DE. Clinical utility of heteroduplex analysis of TCR gamma gene rearrangements in the diagnosis of T-cell lymphoproliferative disorders. Am J Clin Pathol 1997; 108: 295-301.
11. Cox DR. Regression models and life tables. J R Stat Soc (B) 1972; 34: 187-220.
12. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.
13. Frizzera G, Hanto DW, Gajl-Peczalska KJ et al. Polymorphic diffuse B-cell hyperplasias and lymphomas in renal transplant recipients. Cancer Res 1981; 41: 4262-4279.
14. Nalesnik MA, Jaffe R, Starzi TE et al. The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol 1988; 133: 173-192.
15. Knowles MA, Cesarman E, Chadburn A et al. Correlative morphological and molecular genetic analysis demonstrates three distinct categories of posttransplantation lymphoproliferative disorders. Blood 1995: 85: 552-565.
16. Chao NJ, Berry GJ. Advani R et al. Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma. Transplantation 1993; 55: 1425-1428.
17. Shepherd JD, Gascoyne RD, Barnett MJ et al. Polyclonal Epstein-Barr virus-associated lymphoproliferative disorder following autografting for chronic myeloid leukemia. Bone Marrow Transplant 1995; 15: 639-641.
18. Briz M, Fores R, Regidor C et al. Epstein-Barr virus associated B-cell lymphoma after autologous bone marrow transplantation for T-cell acute lymphoblastic leukaemia. Br J Haematol 1997; 98: 485-487.
19. Swerdlow SH. Classification of the posttransplant lymphoproliferative disorders: from the past to the present. Semin Diagn Pathol 1997; 14: 2-7.
20. O'Riordan JM Molloy K, O'Briain DS et al. Localized, late-onset, high-grade lymphoma following bone marrow transplantation: response to combination chemotherapy. Br J Haematol 1994; 86: 183-186.
21. Blanche S, Le Deist F, Veber F et al. Treatment of severe Epstein-Barr virus-induced polyclonal B-lymphocyte proliferation by anti-B-cell monoclonal antibodies. Ann Intern Mcd 1988; 108: 199-203.
22. Rooney CM. Smith CA, Ng CYC et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr virus-related lymphoproliferation. Lancet 1995; 345; 9-13.
23. Lucas KG. Small TN, Heller G et al. The development of cellular immunity to Epstein-Barr virus after allogeneic bone marrow transplantation. Blood 1996; 87: 2594-2603.
24. Heslop HE, Ng CYC, Li C et al. Long-term restoration of immunity against Epstein-Barr virus infection by adoptive transfer of gene-modified virus-specific T lymphocytes. Nature Med 1996; 2: 551-555.